A. Falkner

Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders

R. Greil, M. Fiegl, G. Gastl, 2008 .

Hämatologische Labordiagnostik im interdisziplinären hämatologischen Kompetenzzentrum (IHK) der hämatologisch onkologischen Klinik V der Universitätsklinik Innsbruck und des Zentrallabors der Universitätsklinik Innsbruck/Laboratory examination of hematologic diseases in the Interdiscipline Hematolog

A. Huber, A. Griesmacher, M. Anliker, 2013 .

Laboratory examination of hematologic diseases at the interdisciplinary hematologic competence center (IHK) of Innsbruck of the clinic for hemato-oncology V of the university hospital Innsbruck and the central laboratory of the university hospital Innsbruck (ZIMCL)1)

A. Huber, A. Griesmacher, M. Anliker, 2013 .

Linkage of alterations in systemic iron homeostasis to patients’ outcome in sepsis: a prospective study

A. Vales, G. Weiss, P. Tymoszuk, 2020, Journal of Intensive Care.

Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia

R. Greil, M. Fiegl, G. Gastl, 2006, Cancer.

Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL.

R. Greil, I. Tinhofer, M. Fiegl, 2007 .